$heff's $tation of $tocks & $olid DD

[ash111]

TEAR, 2.42 +8%, volume surges today. DD:

1.Rodman & Renshaw Boostted TearLab Corp (TEAR) Price Target from $2 to $12, recently.

2. In 2016, completed a successful $17.3 million financing.

3. Outstanding Shares 5,367,156 a/o Mar 03, 2017 (Market cap about $11m a/o today) and currently trading below Cash on Hand.

4. Catalysts 2017: https://www.thestreet.com/story/13999168/1/tearlab-provides-update-on-international-market-milestones.html (later this year- System can be commercialized in the largest market in Latin America with a population of over 200 million...).

5. March presentation. go to page 10-Current Anual Revenues and future estimations- also read page 14: Q earnings history grow rate: https://www.tearlab.com/investors/TearLab_Investor_Presentation_March_2017_Web.pdf

Quarterly earnings:
For the three months ended December 31, 2016, TearLab’s net revenues were $7.1 million, up 5% from $6.8 million for the same period in 2015. A net total of 183 TearLab Osmolarity® Systems were added in the fourth quarter of 2016, of which 64 were under the Company’s new Flex program and 26 were purchased outside of the United States.

About the company:
3. TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. On December 31, 2016, we had 75 full-time employee

Recent Developments:
March 3,2017, TearLab Announced CE Marking for Next-Generation System: For the first time, the TearLab next-generation platform offers eye care professionals the ability to assess multiple biomarkers in human tears with a single nanoliter volume tear collection. The lab-on-a-chip platform provides quantitative measurements of tear proteins in a fully automated workflow that is consistent with the current TearLab Osmolarity System which many physicians have incorporated into their practice. This CE Marking provides regulatory clearance for both the device and the initial next-generation test card, capable of measuring both osmolarity and an inflammation biomarker, which together will help identify patients expected to respond to dry eye disease (DED) therapies.

The market research firm, “Markets and Markets” reports the global market for point-of-care testing will reach $37.0 billion annually by 2021
http://www.marketsandmarkets.com/PressReleases/point-of-care-diagnostic.asp

Fourth Quarter and Year End 2016 Financial Results:

* Achieved full-year 2016 revenue of $28.0 million, an increase of 11% over $25.2 million in 2015

* Reduced loss from operations by 49% compared to 2015, from $31.5 million to $16.0 million

* Received CE Mark approval for next generation platform, providing regulatory clearance in the European Union and European Free Trade Association member countries

* Received regulatory approval from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in Mexico
Received regulatory approval in the Republic of Korea by the Ministry of Health and Welfare
Submitted regulatory filing for approval in the Federative Republic of Brazil

* Launched the TearLab Osmolarity System in the Republic of India through partner My HealthSkape PVT Ltd.